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Abstract The anticancer ruthenium–arene compound
[Ru(g6-C6H5CF3)(pta)Cl2] (where pta is 1,3,5-triaza-7-
phosphatricyclo[3.3.1.1]decane), termed RAPTA-CF3,
with the electron-withdrawing a,a,a-trifluorotoluene ligand,
is one of the most cytotoxic RAPTA compounds known. To
rationalize the high observed cytotoxicity, the hydrolysis of
RAPTA-CF3 in water and brine (100 mM sodium chloride)
and its reactions with the protein ubiquitin and a double-
stranded oligonucleotide (50-GTATTGGCACGTA-30) were
studied using NMR spectroscopy, high-resolution Fourier
transform ion cyclotron resonance mass spectrometry, and
gel electrophoresis. The aquation of the ruthenium–chlorido
complex was accompanied by a loss of the arene ligand,
independent of the chloride concentration, which is a spe-
cial property of the compound not observed for other
ruthenium–arene complexes with relatively stable ruthe-
nium–arene bonds. Accordingly, the mass spectra of the
biomolecule reaction mixtures contained mostly [Ru(pta)]–
biomolecule adducts, whereas [Ru(pta)(arene)] adducts
typical of other RAPTA compounds were not observed in
the protein or DNA binding studies. Gel electrophoresis
experiments revealed a significant degree of decomposition
of the oligonucleotide, which was more pronounced in the
case of RAPTA-CF3 compared with RAPTA-C. Conse-
quently, facile arene loss appears to be responsible for the
increased cytotoxicity of RAPTA-CF3.
Keywords Anticancer drugs  Bioorganometallic
chemistry  DNA interactions  Mass spectrometry 
Protein binding
Introduction
In recent years organometallic compounds have received
increased attention as potential anticancer drugs [1, 2].
Different classes of drugs appear to have the potential to
overcome the limitations of current chemotherapeutics,
including drug resistance, activity in a limited number of
tumors, and toxic side effects. Promising compounds
include derivatives of the clinically tested titanocene
dichloride, ferrocene-modified established drugs, square-
planar gold drugs, and ruthenium–arene and osmium–arene
complexes [2–5].
Ruthenium coordination compounds are the most
prominent non-platinum-based anticancer agents, with two
representatives currently undergoing clinical trials [6–8].
The low general toxicity and a mode of action which is
supposed to be different from that of established metal-
based chemotherapeutics make ruthenium compounds
promising drug candidates. The pharmacokinetics upon
intravenous administration of the ruthenium(III) complex
KP1019 revealed rapid and selective binding to serum
proteins, which may prevent ruthenium from being reduced
and its subsequent activation in the blood. Hence,
activation for reaction with target molecules should only
take place in the hypoxic environment of solid tumors,
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providing an extra degree of selectivity for diseased tissue
over healthy cells [7–9]. The best studied organometallic
compounds are based on the ruthenium–arene scaffold and
bear monodentate and bidentate ligands [10–18], including
halides or dicarboxylates as leaving groups and 1,2-ethy-
lenediamine (en), 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]
decane (pta; see Fig. 1 for the structure of the prototype
compound RAPTA-C), pyrone, and paullone derivatives,
etc. as activity-determining moieties. The ligands sur-
rounding the metal center have a strong impact on the
reactivity of the complexes with biological targets, such as
DNA and proteins [19]. Notably, variation of the ligand
sphere allows the design of compounds with antineoplastic
activity against primary tumor or metastasis, as demon-
strated recently for en and pta compounds, respectively
[11, 14], and for the incorporation of desirable properties
such as overcoming drug resistance [20–22]. Most of the
ruthenium-based drug candidates mentioned are capable of
binding strongly to biological nucleophiles. The reactions
of metal complexes bearing halides, mostly chloride, pro-
ceed via their replacement with soft donor atoms, such as
the imidazole of histidine, the thiol of cysteine, or the
thioether of methionine in the case of proteins or with N7
of purine bases, predominantly guanine, in the case of
DNA. A multitude of analytical methods have been used to
characterize the binding of metal drugs to biomolecules
[23–26]. In recent years, mass-spectrometric methods have
emerged as leading tools to analyze complex mixtures of
biomolecules and metal compounds, especially when
coupled with separation methods. These techniques have
been used to determine binding kinetics and stability con-
stants, to characterize the adducts formed (including loss of
ligands), and to identify drug binding sites [5, 23, 25–37].
Recently, a series of compounds of the general formula
[Ru(g6-fluoroarene)(pta)Cl2] (fluoroarene is C6H5F, C6H5
CF3, and 1,4-FC6H4CH3) was designed with the help of
density functional theory calculations, aiming to exploit the
pH difference of tumor cells and a healthy environment by
modulating the pKa values [38]; this feature was already
successfully used in the case of platinum(II) complexes
bearing an aminoalcohol ligand, which can be activated at
lower pH for reactivity towards proteins, DNA, and DNA
model compounds [7, 39–41]. The a,a,a-trifluorotoluene
complex [Ru(g6-C6H5CF3)(pta)Cl2], termed RAPTA-CF3
(see Fig. 1), was found to be the most cytotoxic in A2780
human ovarian cancer cells, and significantly more cyto-
toxic than other simple RAPTA compounds.
To establish, at a molecular level, the reason for the
increased cytotoxicity of RAPTA-CF3, the hydrolysis and
subsequent reactivity of the compound with biomolecules
was studied. RAPTA-CF3 was found to be considerably
more reactive than RAPTA-C, used as a control in the
studies, owing to the facile loss of the a,a,a-trifluorotoluene
ligand, and the outcome of these studies are reported
herein.
Results and discussion
Metal-based drugs tend to undergo activation following
administration and should therefore be considered as pro-
drugs that are activated in vivo. Such metabolization
comprises simple hydrolysis/aquation, which occurs fre-
quently in the case of metallodrugs, and subsequent reac-
tion with proteins, and in the case of platinum complexes,
with their ultimate biotarget DNA. In the case of the
ruthenium(II)–arene compounds, both the reaction with
DNA and that with proteins are considered as potential
steps in the modes of action of prominent representatives.
RAPTA complexes have previously been shown to
undergo rapid hydrolysis in water through loss of a
chlorido ligand [42]. A detailed study of RAPTA-C found
that aquation occurs after only seconds, with an equilib-
rium of 3:1 reached between the dichlorido and mono-
chlorido complexes after 20 min [43]. The hydrolysis
product is observed in the 31P{1H} NMR spectrum as a
second peak, approximately 2 ppm downfield of the peak
for the starting compound. The process is suppressed at
elevated concentration of chloride such as that found in the
bloodstream (100 mM), suggesting that in vivo the drug is
activated on reaching the cell, where the concentration is
considerably lower (4 mM), in a manner similar to cis-
platin [44]. However, it is worth noting that ruthenium–
arene compounds can undergo ligand substitution reactions
via an arene slippage mechanism and hydrolysis is not a
prerequisite for reactivity, and such a mechanism could
allow reaction with serum proteins [12].
The 31P{1H} NMR spectrum of a freshly prepared
solution of RAPTA-CF3 shows a major peak at 30.5 ppm
and a peak at -27.5 ppm of low intensity assigned to
the hydrolysis product [Ru(g6-C6H5CF3)(H2O)Cl(pta)]
?.
When the spectrum is recorded in a solution of 100 mM
NaCl, only the peak at 30.5 ppm is observed, suggesting
that loss of a chlorido ligand to give [Ru(g6-
C6H5CF3)(H2O)Cl(pta)]
? is inhibited. The stability of
RAPTA-CF3 in D2O was monitored by
1H and 31P{1H}
NMR spectroscopy over 72 h. A gradual increase in














Fig. 1 Structures of RAPTA-C (left) and RAPTA-CF3 (right)
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NMR spectra, reaching equilibrium after 24 h at a ratio of
1:2. The aqua product is also observed in the 1H NMR
spectra as a second series of peaks approximately 0.1 ppm
downfield of the peaks of the original complex. After 5 h, a
third peak appears in the 31P{1H} NMR spectrum at
-2.7 ppm, corresponding to uncoordinated, oxidized pta.
The formation of this species is concurrent with the
presence of free arene in the 1H NMR spectrum at
7.3–7.6 ppm, suggesting that both the arene and pta ligands
are released, at least in part, from the resulting ruthenium
complex (Fig. 2). The intensity of these peaks increases
steadily to reach, after 72 h in solution, an equilibrium of
1:1 with the original complex.
When the study was repeated in the presence of 100 mM
NaCl, formation of [Ru(g6-C6H5CF3)(H2O)Cl(pta)]
? was
not observed; however, peaks corresponding to free arene
and oxidized pta were present after only 2 h, and were the
major species in solution after 48 h. This behavior is quite
different from that of other RAPTA compounds, which are
stable for several days in 100 mM NaCl solution and do
not generally undergo loss of the arene ligand. The strongly
electron withdrawing nature of the C6H5CF3 ligand results
in a comparatively weak ruthenium–arene bond, and is
presumably responsible for the higher cytotoxicity of the
complex.
Biomolecule binding studies
To estimate the reactivity of RAPTA-CF3 towards proteins,
the ruthenium complex was incubated with the model pro-
tein ubiquitin (Ub) at a molar ratio of 2:1 (complex to
protein) and the reaction was monitored by analyzing the
reaction mixture after 1 and 3 days using electrospray
ionization Fourier transform ion cyclotron resonance mass
spectrometry (ESI-FT-ICR-MS) in positive ion mode. Prior
to flow injection into the mass spectrometer, the sample was
diluted 1:100 with a water/acetonitrile/1% formic acid
solution, to improve the spraying. The broadband spectra
acquired in the range m/z 770–870 are shown in Fig. 3 (Ub
charge states 11? and 10?). The spectra are dominated by
two main peaks corresponding to unreacted Ub at m/z
779.61004 and 857.47032. In addition, in both spectra
recorded following incubation with RAPTA-CF3 (at 1 and
3 days) a series of peaks are observed that correspond to
adducts of Ub containing fragments of RAPTA-CF3. In
contrast to results reported for the structurally similar
RAPTA-C [19], the arene ligand is cleaved off in the case of
RAPTA-CF3 during the reaction with the protein and
mainly adducts of the type [Ub–Ru(pta)(H2O)x] (x = 0–2)
were identified after 1-day reaction (Fig. 3). This result is
consistent with the observations during the hydrolysis
studies (see earlier). Notably, also an adduct of Ub with
solely ruthenium was identified, and in the range m/z 790–
800 numerous species containing aqua and acetonitrile
ligands, which originated from the solution used to improve
the spray efficiency, were assigned to m/z values. In the m/z
range 800–810 a series of aqua, acetonitrile, and chloride
species were identified. However, several signals over-
lapped and could not be resolved, although the mass spectra
were recorded in high-resolution mode (R & 80,000 at m/z
400). After 1-day incubation, the most abundant ruthenium-
containing adduct peak was assigned to [Ub ? Ru(pta)]
with a relative intensity of 28% (Table 1), with regard to the
most abundant signal in the spectrum at m/z 779.61083, i.e.,
[Ub ? 11H]11?. Furthermore, a peak was identified as



















Fig. 2 1H NMR hydrolysis
studies of RAPTA-CF3 in D2O
(left) over 24 h, showing that
the arene ligand is released over
time and aqua species are
formed. In brine the degree of
arene loss is significantly higher
(right). Peak assignment:
a arene, b RAPTA-CF3,
c hydrolysis products
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indicate at least partial degradation of the protein. In general
the mass accuracy was very good with errors usually 1 ppm
or less, enabling exact assignment of a manifold of Ub–Ru
species (Table 1). Upon incubation for 3 days, the spectra
contained fewer and less abundant adduct peaks compared
with incubation for 1 day. [Ub ? 11H]11? remained the
most abundant peak in the mass spectrum, followed
by [Ub ? Ru(pta)(H2O) ? 9H]
11? (10%) and [Ub ?
Ru(pta) ? 9H]11? (8%).
To evaluate the reactivity of RAPTA-CF3 with DNA,
the complex was incubated with a double-stranded 13-mer
oligonucleotide (consisting of 50-GTATTGGCACGTA-30,
S1, and 30-TACGTGCCAATAC-50, S1c) at a molar ratio
of 1:1 (final DNA concentration 10 lM) in water at 37 C.
Aliquots were taken after 0.25, 1, 3, 9, and 24 h and ana-
lyzed by ESI-FT-ICR-MS with respect to adduct formation.
Under the spraying conditions applied, the oligonucleotide
was separated into its complementary single strands,
which were fourfold to eightfold negatively charged and
most abundant at charge states 6– and 7–. Hence, only
this region is discussed and depicted in Fig. 4. The
monoadduct of Ru(pta) with S1c [S1c ? Ru(pta) – 9H]7-
at m/z 595.37471 rapidly became the most prominent peak
after incubation for 1 h. At this time, signals corresponding
to two Ru(pta) complexes per single strand started to arise
and became the second-most abundant peaks after 3 h of
incubation. It is noteworthy that all of these adducts are
accompanied by a series of aqua adducts (indicated with
asterisks in Fig. 4), which were clearest at lower charge
states (up to three aqua adducts per DNA strand in case of
the [Ru(pta)]2 adduct). Further signals, corresponding to
Ru(pta) adducts upon elimination of one adenine or
guanine (Fig. 4, indicated with triangles and circles,
respectively) from the single-stranded oligonucleotides and
consecutive addition of H2O, were less abundant, but were
present throughout the study. These base losses seem to be
unspecific as they were also observed in previously
published studies with cisplatin under the same
conditions [34]. No peaks corresponding to Ru(pta)Cl,
Ru(a,a,a-trifluorotoluene)(pta), or Ru(a,a,a-trifluorotolu-
ene)(pta)Cl adducts were observed at any time, indicating
quick and complete loss of the arene and chlorido ligands
takes place.
Owing to the high resolution of the ion cyclotron reso-
nance technique, isotopic peak patterns were completely
resolved and used together with the high-accuracy mass
determination for unambiguous identification of the above-
mentioned peaks. Figure 5 shows a comparison of the
theoretical peak pattern, including the calculated m/z value
for the most abundant isotopic peak, with the experimental
Fig. 3 The reaction of ubiquitin (Ub) with RAPTA-CF3 after 0, 24,
and 72 h. Peak assignment: a [Ub ? Ru ? 9H]11?, b [Ub ?
Ru(CH3CN) ? 9H]
11?, c [Ub ? Ru(CH3CN)2 ? 9H]
11?, d [Ub ?
Ru(pta) ? 9H]11? (pta is 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]
decane), e [Ub ? Ru(pta)(H2O) ? 9H]
11?, f [Ub ? Ru(pta)Cl ?
10H]11?, g [29PG76 ? 8H]8?
Table 1 Selected ubiquitin (Ub) adducts formed with RAPTA-CF3 and their relative abundances after 1 and 3 days of reaction, observed and
theoretical m/z values, and the mass accuracy
Identified species Relative abundance (%) Theoretical m/z Experimental
(1 day) m/z
Error (ppm)
1 day 3 days
[Ub ? 11H]11? 100 100 779.61004 779.61083 1.01
[Ub ? Ru ? 9H]11? 13 4 788.59989 788.60007 0.22
[Ub ? Ru(CH3CN) ? 9H]
11? 5 – 792.32958 792.32959 0.01
[Ub ? Ru(CH3CN)2 ? 9H]
11? 6 3 796.05927 796.05982 0.69
[Ub ? Ru(pta) ? 9H]11? 28 8 802.87962 802.87995 0.41
[Ub ? Ru(pta)(H2O) ? 9H]
11? 19 10 804.51694 804.51650 0.55
[Ub ? Ru(pta)Cl ? 10H]11? 16 – 806.24115 806.24180 0.80
[29PG76 ? 8H]8? 11 9 817.31944 817.32026 1.00
[Ub ? 10H]10? 69 55 857.47032 857.47098 0.77
pta 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane
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pattern for the Ru(pta) and [Ru(pta)]2 adducts, i.e.,
[S1c ? Ru(pta) - 9H]7-, [S1 ? Ru(pta) - 9H]7-, [S1c ?
2 Ru(pta) - 9H]5-, and [S1 ? 2 Ru(pta) - 11H]7- at
m/z 595.37403, 605.51720, 631.94088, and 899.32065. An
analogous comparison for the [oligo - B(AH)/B(GH) ?
Ru(pta) ? H2O] pattern is given in Fig. S1. As the accu-
racy was typically less than 1 ppm and the peak patterns
were identical, accurate assignment of the signals was
achievable. Table 2 lists the m/z values of the most abun-
dant isotopic peaks of the assigned signals.
The reactivity of RAPTA-C and RAPTA-CF3 with the
oligonucleotide was directly compared at drug-to-oligo-
nucleotide ratios of 1:1 and 5:1 upon incubation for 1 and
3 days. For identification of adducts, ESI-FT-ICR-MS was
used, and polyacrylamide gel electrophoresis (PAGE) was
applied to visualize the structural changes to the DNA
(e.g., formation of dimers and degradation of DNA).
Mass spectra of a solution containing a fivefold excess
of RAPTA-CF3 or RAPTA-C with the oligonucleotide
following incubation for 24 h are depicted in Fig. 6.
RAPTA-CF3 preferably releases the two chlorido ligands
and the arene ligand, but not the pta ligand, leading to
Ru(pta) adducts as described previously. In contrast,
RAPTA-C mainly forms Ru(pta)(g6-p-cymene) adducts
and only a small amount of oligonucleotide–Ru(pta) was
detected, indicating that the introduction of the electron-
withdrawing CF3 group into the arene weakens the ruthe-
nium–arene bond, which is accordingly more easily
cleaved off in the case of RAPTA-CF3 compared with the
p-cymene ligand in RAPTA-C. Consecutively, the vacant
positions in the coordination sphere of ruthenium may be
occupied by aqua ligands, which explains the series of
Ru(pta)(H2O)x signals in case of RAPTA-CF3, which do
not accompany the Ru(pta)(arene) adduct that is formed in
case of RAPTA-C. Hence, the aqua species are unlikely to
originate from incomplete desolvatization during electro-
spray ionization.
Following 3 days of incubation of the oligonucleotide
with a fivefold excess of RAPTA-CF3, no peaks that could
be readily assigned to the intact oligonucleotide or RAP-
TA-CF3 modified adducts were observed. Indeed, none of
the above-mentioned peaks were observed, indicating that
degradation of the oligonucleotide had occurred (as also
observed in the case of RAPTA-C). To verify this proposal,
reaction mixtures of RAPTA-C and RAPTA-CF3 with
Fig. 4 Charge state 7– of the full-scan mass spectra recorded upon
incubation of 10 lM RAPTA-CF3 with an equivalent amount of
double-stranded oligonucleotide in water for the time points indi-
cated. Under the ionization conditions applied, strands were detected
separately in the mass spectrometer [30-TACGTGCCAATAC-50
(S1c) light gray and 50-GTATTGGCACGTA-30 (S1) dark gray].
Adducts of Ru(pta) and [Ru(pta)]2 are formed. Asterisks indicate
analogous water adducts to the adjacent identified peak. Triangles and
circles indicate [Ru(pta) ? H2O] adducts with loss of adenine or
guanine, respectively
Fig. 5 Comparison of calculated peak patterns with experimental isotopic distributions of selected adducts
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DNA incubated for 1 and 3 days were separated by PAGE
(Fig. 7, Table 3). Incubation of DNA with an equimolar
amount of complex showed no significant degradation
upon 24-h reaction (95 and 90% of intact DNA for RAP-
TA-C and RAPTA-CF3, respectively), whereas the DNA
content upon 3 days of incubation was reduced to
approximately 65 and 60%. In the case of a fivefold excess
of complex over DNA, degradation was more prominent:
in the case of RAPTA-C approximately 30% of DNA was
still intact, whereas only approximately less than 10% of
DNA was intact in the case of RAPTA-CF3 within 24 h of
incubation. Both complexes continued to degrade the
DNA, leading to less than 10% of DNA being intact after
3 days of incubation. However, these data should not be
considered as absolute values, since ethidium bromide
intercalation might be affected by the presence of the
complexes.
Table 2 Selected oligonucleotide adducts formed with RAPTA-CF3
Identified species Theoretical m/z Experimental m/z Error (ppm)
[S1c - 7H]7- 558.66501 558.66495 0.11
[S1 - 7H]7- 568.80797 568.80796 0.02
[S1c - B(GH) ? H2O ? Ru(pta) – 9H]
7- 576.36914 576.36840 1.28
[S1c – B(AH) ? H2O ? Ru(pta) – 9H]
7- 578.65415 578.65371 0.76
[S1 – B(GH) ? H2O ? Ru(pta) – 9H]
7- 586.51212 586.51218 0.10
[S1 – B(AH) ? H2O ? Ru(pta) – 9H]
7- 588.79711 588.79695 0.27
[S1c ? Ru(pta) – 9H]7- 595.37471 595.37403 1.14
[S1c ? Ru(pta)(H2O) – 9H]
7- 597.94765 597.94695 1.17
[S1 ? Ru(pta) – 9H]7- 605.51768 605.51720 0.80
[S1 ? Ru(pta)(H2O) – 9H]
7- 608.09062 608.09024 0.62
[S1 ? Ru(pta)(H2O)2 – 9H]
7- 610.66355 610.66295 0.98
[S1c ? 2 Ru(pta) – 11H]7- 631.94131 631.94088 0.68
[S1c ? Ru(pta) ? Ru(pta)(H2O) – 11H]
7- 634.51425 634.51347 1.22
[S1 ? 2 Ru(pta) – 11H]7- 642.08428 642.08402 0.40
[S1 ? Ru(pta) ? Ru(pta)(H2O) – 11H]
7- 644.65722 644,65664 0.90
[S1 ? 2 Ru(pta)(H2O) – 11H]
7- 647.23016 647.23009 0.11
[S1c – 6H]6- 651.94372 651.94371 0.02
[S1 – 6H]6- 663.77718 663.77726 0.12
S1 50-GTATTGGCACGTA-30, S1c 30-TACGTGCCAATAC-50
Fig. 6 Comparison of the reaction of RAPTA-CF3 and that of
RAPTA-C with a double-stranded oligonucleotide by electrospray
ionization mass spectrometry (1 day, ruthenium complex to oligonu-
cleotide ratio 5:1 in water at 37 C). Asterisks indicate water adducts















































Fig. 7 Gels showing RAPTA-CF3 and RAPTA-C treated oligonu-
cleotide mixtures at incubation ratios of 1:1 and 5:1 following
separation
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Conclusions
Ruthenium–arene compounds with a pta ligand, including
RAPTA-C as the prototype species, are anticancer drug
candidates with notable activity against metastases. RAP-
TA-CF3 represents a special compound designed with the
aim of exploiting one of the different properties of normal
and cancer tissues, namely, a significantly lower pH, to
achieve higher selectivity in the treatment of cancer [38]. It
is noteworthy that RAPTA-CF3 is more cytotoxic than
RAPTA-C and other RAPTA compounds. We were able to
trace this greater cytotoxicity to the greater reactivity of
RAPTA-CF3 over RAPTA-C due to the facile loss of the
electron-poor a,a,a-trifluorotoluene ligand.
Hydrolysis studies showed that the a,a,a-trifluorotoluene
ligand is released after dissolution in aqueous media. A similar
feature was observed in the reactions of RAPTA-CF3 with
biomolecules; incubation with the model protein Ub and a
short double-stranded oligonucleotide resulted in adduct
peaks which are mainly assignable to [Ru(pta)]–biomolecule
ions, i.e., with the arene and chlorido ligands cleaved off. The
release of the arene ligand allows the formation of rather
different biomolecule adducts as compared with classic
bifunctional platinum compounds or the parent compound
RAPTA-C, with the biomolecule acting as a multidentate
ligand. This might have important implications for the mode
of action of RAPTA-CF3, as such adducts might resist repair
by DNA repair enzymes (should DNA prove to be the target).
Furthermore, PAGE studies show that compared with RAP-
TA-C, RAPTA-CF3 has stronger potential to degrade DNA.
In the case of proteins, such multidentate binding might cause
significant structural modifications, resulting in altered func-
tions of potential target enzymes.
Materials and methods
RAPTA-C [10] and RAPTA-CF3 [38] were prepared as
described previously.
Hydrolysis studies
The hydrolytic stability of RAPTA-CF3 was determined by
1H and 31P{1H} NMR spectroscopy without light protec-
tion. Solutions of RAPTA-CF3 (1 mM) in D2O (or D2O
containing 100 mM NaCl; pH 5.4–5.8) were incubated at
37 C over 72 h and aliquots were taken after 0, 0.5, 1, 2,
3, 5, 8, 12, 24, 48, and 72 h. 1H and 31P{1H} NMR spectra
were recorded at 400.13 and 161.98 MHz with a Bruker
Avance DPX spectrometer at room temperature using
SiMe4 and H3PO4 as external standards, respectively.
Protein and (oligo)nucleotide binding studies
Sample preparation
The high performance liquid chromatography purified
double-stranded 13-mer oligonucleotide S1 was purchased
as an aqueous solution with a concentration of 0.2 mM
from A/S Technology (Denmark) and was checked by
PAGE for complete annealing. RAPTA-CF3 and RAPTA-
C were dissolved in water (200 lM stock solutions) and
immediately incubated with the oligonucleotide at effective
complex to double-stranded oligonucleotide molar ratios of
1:1 and 5:1 in a total volume of 300 ll in Eppendorf vials
(500 ll) in a thermomixer (300 rpm; Eppendorf) at 37 C.
Evaporation was minimized by sealing the tubes with
Parafilm M and covering them with several layers of
aluminum foil. To investigate the binding kinetics of
RAPTA-CF3, aliquots of 30 ll were taken after 0.25, 1, 3,
9, and 24 h of incubation; for direct comparison of RAP-
TA-C and RAPTA-CF3, aliquots were taken after 1 and
3 days of incubation. All samples were stored at -20 C
until analysis by mass spectrometry or PAGE.
For mass-spectrometric analysis, the aqueous samples
were thawed completely and an aliquot of 10 ll was
diluted immediately prior to analysis with 40 ll of a
1.25 mM ammonium acetate solution in 65:10:5 (v/v/v)
MeOH/water/1-propanol, resulting in the following final
spraying conditions: 2 lM oligonucleotide, 1 mM ammo-
nium acetate, and 65:30:5 MeOH/water/1-propanol.
For the protein binding studies, RAPTA-CF3 was
incubated with Ub (from bovine red blood cells, minimum
90%; Sigma) at a molar ratio of 2:1 in water (final protein
concentration 100 lM) and samples were taken after 24
and 72 h of incubation at 37 C. The samples were diluted
1:100 with 70:30:1 (v/v/v) H2O/CH3CN/HCOOH and were
immediately analyzed by mass spectrometry.
Mass spectrometry
For electrospray ionization mass spectrometry, the samples
were placed into a 96-well plate in an Advion TriVersaTM
Table 3 Quantification of DNA degradation in polyacrylamide gel
electrophoresis analysis as a function of incubation ratios and time
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robot (Advion Biosciences, Ithaca, NY, USA) equipped with
a 5.5-lm nozzle chip. The electrospray ionization robot was
controlled with ChipSoft version 7.2.0 employing the fol-
lowing parameters: for oligonucleotides, gas pressure
0.40 psi, voltage -1.8 to -2.0 kV, sample volume 10 ll,
negative ion mode; for protein binding studies, 0.90 psi,
voltage 1.4–1.6 kV, sample volume 25 ll, positive ion
mode. The samples were analyzed using an ion trap Fourier
transform ion cyclotron resonance mass spectrometer com-
prising an LTQ XL and an 11-T Fourier transform ion
cyclotron resonance mass spectrometer (both from Thermo
Fisher Scientific, Bremen, Germany). The Xcalibur software
bundle (version 2.0.5, Thermo Fischer Scientific) was uti-
lized for data acquisition (Tune Plus version 2.2 SP1;
Thermo Fisher Scientific) and data analysis (Qual Browser
version 2.2; Thermo Fisher Scientific). Oligonucleotide
mass spectra were recorded at a resolution of 75,000 at
500 m/z for m/z 350–2,000. One scan consisted of five mi-
croscans, AGC was set to 1 9 106, the maximum injection
time of 500 ms was never exceeded, and the spectrum was
averaged over at least 50 scans. The mass spectra were re-
calibrated using the charge distributions of single-stranded
S1c (charge states 4– to 8–). Protein binding data were col-
lected in ion trap (m/z 400–2,000), Fourier transform ion
cyclotron resonance (m/z 400–2,000, resolution of 75,000 at
m/z 400), and WSIM (m/z 770–870; resolution of 40,000 at
m/z 800) modes. The mass spectra were recalibrated using
the 10? and 11? charge states of Ub as internal standards in
the positive ion mode.
Gel electrophoresis
Samples were thawed and 10-ll aliquots (0.8 lg oligonu-
cleotide) were mixed with 2 ll of 69 sample buffer and
completely loaded on a native 20% polyacrylamide gel.
Puc-mix (smallest oligonucleotide 45 bp) was used as a
mass ruler in the two outermost lanes and pure double-
stranded DNA of sequence 50-GTATTGGCACGTA-30
(S1) was used in amounts of 0.8, 0.4, and 0.08 lg as
standards for estimation of the concentration of the oligo-
nucleotide upon incubation with the metal complexes.
Tris(hydroxymethyl)aminomethane–borate–EDTA buffer
(19) was used as electrolyte and electrophoresis was per-
formed at a constant current (12 mA) for 3–4 h. Gels were
stained with ethidium bromide (0.5 lg/ml) for 15–20 min
and visualized by UV light irradiation. Quantification of
DNA bands was performed with ImageJ (National Insti-
tutes of Health, USA).
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